139 related articles for article (PubMed ID: 8319246)
1. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
[TBL] [Abstract][Full Text] [Related]
2. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993; 36(4):229-36. PubMed ID: 8439986
[TBL] [Abstract][Full Text] [Related]
3. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M; Siessmann KL; Mokyr MB; Dray S
Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
[TBL] [Abstract][Full Text] [Related]
4. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
5. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Barker E; Mokyr MB
Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.
Wise JA; Mokyr MB; Dray S
Cancer Res; 1989 Jul; 49(13):3613-9. PubMed ID: 2567207
[TBL] [Abstract][Full Text] [Related]
7. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
Weiskirch LM; Bar-Dagan Y; Mokyr MB
Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
[TBL] [Abstract][Full Text] [Related]
9. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
10. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.
Satoh K; Kan N; Okino T; Nakanishi M; Mise K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
Cancer Immunol Immunother; 1991; 32(5):273-9. PubMed ID: 1998969
[TBL] [Abstract][Full Text] [Related]
11. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
12. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
13. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
Sojka DK; La Motte RN; Mokyr MB
Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
[TBL] [Abstract][Full Text] [Related]
14. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
15. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
16. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
18. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
[TBL] [Abstract][Full Text] [Related]
19. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
[TBL] [Abstract][Full Text] [Related]
20. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
